IAICC 2025
Convention
MAY 2-3, 2025
Ronald Reagan Building and International Trade Center 1300 Pennsylvania Avenue, NW Washington, DC 20004
FDAMap CEO, Dr. Mukesh Kumar, to Speak on “Global Drug Development Strategies” at IAICC 2025 Convention
Gaithersburg, MD – April 2024 – FDAMap is pleased to announce that our CEO, Dr. Mukesh Kumar, has been invited to deliver a presentation on “Global Drug Development Strategies in the New Political Environment” at the upcoming IAICC 2025 Convention, scheduled for May 2–3 in Washington, D.C.
About the Event
The IAICC 2025 Convention, following the success of its 30th Anniversary event in 2023, will convene during a pivotal period of political and economic transition in the United States. With a new presidential administration and an uncertain economic climate, the convention aims to explore how evolving policies may impact US-India relations and the broader global business environment. Key sectors likely to be affected include AI, Science & Technology, Security & Defense, Energy, Infrastructure, Health & Pharmaceuticals, Environmental Sciences, Agriculture, and Education.
This two-day event in Washington, DC, will offer critical insights into the implications of policy shifts and present strategies for the business community to adapt to emerging challenges. Attendees will have the opportunity to evaluate the economic priorities of the new administration, understand their effects on global collaborations, and identify ways to maintain and strengthen the growing US-India partnership.
High-level US Government dignitaries, representatives from public sector agencies such as SBA, MBDA, and OSDBU, as well as experts in Acquisition and Mentor Protégé programs, will participate. International government officials, industry executives, and thought leaders will also contribute their perspectives, making the convention a key platform for strategic dialogue, networking, and the formulation of actionable business strategies amid political and economic uncertainty.
About FDAMap
FDAMap is a full-service CRO specializing in regulatory guidance, clinical trial management, and strategic planning for biopharma and regenerative medicine companies. Under the leadership of Dr. Mukesh Kumar, FDAMap has been instrumental in advancing innovative treatments like GIOSTAR’s cutting-edge stem cell therapies, guiding them through the complex FDA approval process. FDAMap is proud to play a key role in ensuring these transformative therapies reach patients in need.
Stay connected for updates on new breakthroughs and other projects by following FDAMap on LinkedIn or subscribing to our newsletter at www.fdamap.com. For direct inquiries, contact us today.
Media Contact:
Prashant Kumar
Director of Communications
FDAMap
Phone: +1-410-501-5777
Email: pkumar@fdamap.com